SCHEMBL450015

SCHEMBL450015

COc1ccc(-n2c(C(C)N(C)S(=O)(=O)c3ccc(-c4ccccc4)cc3)nc3ccc(OC)cc3c2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
CXCR3 P49682 4/20 0.45
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
G6PD P11413 1/20 0.41
LMNA P02545 2/20 0.41
CASR P41180 1/20 0.41
C1R P00736 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
MEN1 O00255 2/20 0.40
CYP1A2 P05177 2/20 0.40
KMT2A Q03164 2/20 0.40
USP2 O75604 1/20 0.40
CASP1 P29466 1/20 0.40
BRCA1 P38398 1/20 0.40
CASP7 P55210 1/20 0.40
HBB P68871 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL450081 0.94 ALDH1A1 (0.48) ALDH1A1CXCR3RAB9ANPSR1G6PD
SCHEMBL449758 0.93 PDE10A (0.47) ALDH1A1CXCR3RAB9ANPSR1
SCHEMBL452066 0.90 CXCR3 (0.42) ALDH1A1CXCR3LMNACA2CA9
SCHEMBL454282 0.90 ALDH1A1 (0.50) ALDH1A1CXCR3RAB9ANPSR1G6PD
SCHEMBL450952 0.89 EGFR (0.49) ALDH1A1CXCR3RAB9ANPSR1G6PD
SCHEMBL451745 0.89 CXCR3 (0.55) ALDH1A1CXCR3RAB9ANPSR1G6PD
SCHEMBL451680 0.88 CXCR3 (0.41) ALDH1A1CXCR3CASRCA2CA9
SCHEMBL449020 0.88 ALDH1A1 (0.44) ALDH1A1CXCR3RAB9ANPSR1
SCHEMBL454537 0.87 SMN1; SMN2 (0.53) ALDH1A1CXCR3RAB9AMEN1KMT2A
SCHEMBL452196 0.87 PDE10A (0.49) ALDH1A1CXCR3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US claimed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP claimed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885CXCR3 741/4885RAB9A 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.